Cancer Chemotherapy and Biotherapy -

Cancer Chemotherapy and Biotherapy

Principles and Practice
Buch | Hardcover
848 Seiten
2010 | 5th edition
Lippincott Williams and Wilkins (Verlag)
978-1-60547-431-1 (ISBN)
219,95 inkl. MwSt
zur Neuauflage
  • Titel erscheint in neuer Auflage
  • Artikel merken
Zu diesem Artikel existiert eine Nachauflage
A comprehensive reference on the preclinical and clinical pharmacology of anticancer agents. Organized by drug class, it provides information on various drugs and biological agents - their mechanisms of action, interactions with other agents, toxicities, side effects, and mechanisms of resistance.
Updated to include the newest drugs and those currently in development, Cancer Chemotherapy and Biotherapy, Fifth Edition is a comprehensive reference on the preclinical and clinical pharmacology of anticancer agents. Organized by drug class, the book provides the latest information on all drugs and biological agents—their mechanisms of action, interactions with other agents, toxicities, side effects, and mechanisms of resistance. Chapters emphasize pharmacology and mechanisms of action at the molecular and cellular levels, followed by clinical activity and toxicity, both acute and delayed. The authors explain the rationale for use of drugs in specific schedules and combinations and offer guidelines for dose adjustment in particular situations.

This edition's introduction includes timely information on general strategies for drug usage, the science of drug discovery and development, economic and regulatory aspects of cancer drug development, and principles of pharmacokinetics. Eight new chapters have been added and more than twenty have been significantly revised.

A companion website includes the fully searchable text and an image bank.

Section 1: BASIC PRINCIPLES OF CANCER TREATMENT

1: Clinical Strategies for Cancer Treatment: The Role of Drugs
Bruce Chabner

2: Target Identification and Drug Discovery
Ed Sausville

3: Clinical Drug Development and Approval for Marketing
Thomas Roberts

4: Principles of Pharmacokinetics
Jerry Collins

5: Special Aspects of Brain Tumor Chemotherapy
Jeffrey Supko & Tracy Batchelor

6: Pharmacogenetics
Howard McLeod

7: Barriers to Drug Delivery
Brendan Curti

Section 2: CYTOTOXIC AGENTS

8: Antifolates
Carmen Allegra & Bruce Chabner

9: Fluoro-pyrimidines
David Ryan, Bruce Chabner & Ray Wadlow

10: Cytidine Analogues
David Ryan & Bruce Chabner

11: Purine Analogues
Ken Hande

12: Hydroxyurea
Bruce Chabner

13: Antimitotic Drugs
Ross Donehower

14: Alkylating Agents (Including Methylating Agents)
Stan Gerson & Henry Friedman

15: Platinum Analogues
Ed Reed

16: Antitumor Antibiotics (Including Bleomycin)
Bruce Chabner

17: Topoisomerase I Inhibitors
Alex Spaareboom & William Zamboni

18: Topoisomerase II Inhibitors: Anthracyclines
Jim Doroshow

19: Topoisomerase II Inhibitors: Etoposide, Teniposide
George Hartman & Yves Pommier

20: L-Asparaginase
Bruce Chabner & Alison Friedmann

Section 3: MOLECULARLY TARGETED THERAPIES

21: Proteosome Inhibitors
Orhan Sezar

22: HDAC Inhibitors
Susan Bates

23: Differentiating Agents (Retinoids)
Bruce Chabner

24: Arsenic Trioxide
Bruce Chabner

25: Monoclonal Antibodies: Discovery & Development
David Scheinberg

26: Anti-angiogenic Agents (Including MonAB)
William Gradishar & Kari Wisinski

27: Anti-EGFR Therapies (Including MonAB)
Lecia Sequist & Joel Neal

28: Anti-her 2 Therapies
Eric Winer

29: Intracellular Signal Inhibitors (bcr-abl)
Bruce Chabner & Jeffrey Barnes

30: Signal Transduction Inhibitors in Development
Jeff Clark

31: Inhibitors of the PI3k Pathway & Mitotic Kinase
Percy Ivy

Section 4: IMMUNOLOGIC AGENTS

32: Interferon and Cytokines
David McDermott

33: Vaccines
Robert G. Fenton

34: Adoptive Cellular Therapies
Cassian Yee

35: Immuno-modulatory Drugs (IMIDS, Anti-CTLA4)
Paul Richardson et al.

Section 5: HORMONAL THERAPY

36: Hormonal Therapy of Breast Cancer
Beverly Moy & Paul Goss

37: GNRH Agonists and Anti-Androgens
Richard Lee

Section 6: SUPPORTIVE CARE

38: Pain Management in Cancer Patients
Paul Glare

39: Colony Stimulating Factors
Gary Lyman

40: Anti-nausea Medications
Ian Olver

41: Bone Loss Modulators
Matthew Smith

42: Intravenous Access and Catheter Management
Rachel Rosovsky

Section 7: SURVIVORSHIP

43: Monitoring for Late Side Effects of Chemotherapy
Richard Schilsky, Charles Erlichman & Brian Costello

Verlagsort Philadelphia
Sprache englisch
Maße 213 x 276 mm
Gewicht 2155 g
Themenwelt Medizin / Pharmazie Medizinische Fachgebiete Onkologie
ISBN-10 1-60547-431-2 / 1605474312
ISBN-13 978-1-60547-431-1 / 9781605474311
Zustand Neuware
Haben Sie eine Frage zum Produkt?
Mehr entdecken
aus dem Bereich

von Hannes Leischner

Buch | Softcover (2023)
Urban & Fischer in Elsevier (Verlag)
27,00

von Stein Husebø; Gebhard Mathis; Eva Katharina Masel

Buch | Softcover (2023)
Springer (Verlag)
49,99